The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The Development of Third-Generation Tetracycline Antibiotics and New Perspectives
Open accessAbstract
The tetracycline antibiotic class has acquired new valuable members due to the optimisation of the chemical structure. The first modern tetracycline introduced into therapy was tigecycline, followed by omadacycline, eravacycline, and sarecycline (the third generation). Structural and physicochemical key elements which led to the discovery of modern tetracyclines are approached. Thus, several chemical subgroups are distinguished, such as glycylcyclines, aminomethylcyclines, and fluorocyclines, which have excellent development potential. The antibacterial spectrum comprises several resistant bacteria, including those resistant to old tetracyclines. Sarecycline, a narrow-spectrum tetracycline, is notable for being very effective against Cutinebacterium acnes. The mechanism of antibacterial action from the perspective of the new compound is approached. Several severe bacterial infections are treated with tigecycline, omadacycline, and eravacycline (with parenteral or oral formulations). In addition, sarecycline is very useful in treating acne vulgaris. Tetracyclines also have other non-antibiotic properties that require in-depth studies, such as the anti-inflammatory effect effect of sarecycline. The main side effects of modern tetracyclines are described in accordance with published clinical studies. Undoubtedly, this class of antibiotics continues to arouse the interest of researchers. As a result, new derivatives are developed and studied primarily for the antibiotic effect and other biological effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517
Update on acquired tetracycline resistance genes
Roberts, M. C. (2005) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2005.02.034 · Cited by 1,010
Brodersen, D. E., Clemons, W. M., Carter, A. P., Morgan-Warren, R. J., Wimberly, B. T., & Ramakrishnan, V. (2000) · Cell · doi:10.1016/s0092-8674(00)00216-6 · Cited by 950 · cited 1×
“Thus, the protein synthesis is stopped (Figure 12) [18,81,82].”
BackgroundMinocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Tetracyclines: Antibiotic action, uptake, and resistance mechanisms
Schnappinger, D., & Hillen, W. (1996) · Archives of Microbiology · doi:10.1007/s002030050339 · Cited by 484 · cited 1×
“Later on, the Donnan potential generated along the outer membrane causes the accumulation of the complex in the periplasmic space, where the dissociation from the Mg2+ ion of tetracycline takes place and there is a release of an electrically uncharged molecule that is lipophilic enough to diffuse through the inner mem…”
BackgroundEfflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
Jenner, L., Starosta, A. L., Terry, D. S., Mikolajka, A., Filonava, L., Yusupov, M., Blanchard, S. C., Wilson, D. N., & Yusupova, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216691110 · Cited by 204
Visalli, M. A., Murphy, E., Projan, S. J., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.665-669.2003 · Cited by 165
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic
Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., Wilson, D. N., & Sutcliffe, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06187-11 · Cited by 162
Non-antibiotic properties of tetracyclines and their clinical application in dermatology
Perret, L. J., & Tait, C. P. (2014) · Australasian Journal of Dermatology · doi:10.1111/ajd.12075 · Cited by 68 · cited 1×
“This mechanism occurs both directly and indirectly by inhibiting the MMPs synthesis [96].”
BackgroundMaxwell, I. H. (1967) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(67)90494-7 · Cited by 37
Cited by
Mahmud, Z., Manik, M. R. K., Rahman, A., Karim, M. M., & Islam, L. N. (2024) · Scientific Reports · doi:10.1038/s41598-024-71472-6 · Cited by 22
Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline
Li, X., Wang, M., Denk, T., Buschauer, R., Li, Y., Beckmann, R., & Cheng, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49797-7 · Cited by 21
“The authors chose a complex containing the hibernation factor CCDC124 for discussion, as it “contains all tigecycline binding sites observed in other states”.”
T cell toxicity induced by tigecycline binding to the mitochondrial ribosome
Shao, Q., Khawaja, A., Nguyen, M. D., Singh, V., Zhang, J., Liu, Y., Nordin, J., Adori, M., Axel Innis, C., Castro Dopico, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59388-9 · Cited by 16
Metadata
- Authors
- Rusu, A., & Buta, E. L.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-12-05
- Volume
- 13
- Issue
- 12
- Pages
- 2085
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4200357335
- Cited by
- 210
- References
- 11
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.